ViroPharma VPHM

  1. All
  2. Commentary
  3. Headlines
    1. As Expected, AbbVie and Shire Agree on Takeover Terms; Deal Expected to Close in 4Q


      Fri, 18 Jul 2014

      billion from strong sales of Vyvance (up 20%) and other products and the inclusion of Cinryze sales from the acquisition of Viropharma . The strong top-line growth, coupled with an improving operating margin, resulted in adjusted non-GAAP EPS growth of

    2. Shire's Strong First Quarter Benefited From ViroPharma and Underlying ADHD Demand


      Thu, 1 May 2014

      cost-cutting success, and the close of the ViroPharma acquisition. Management also lowered ..... million in two months since the ViroPharma acquisition), and Lialda (up $28 million or 28%). Excluding ViroPharma , sales were up 11%. Firazyr sales

    3. Shire's 2013 In Line; Raising Our Fair Value on Higher ViroPharma Profit, Lower Cost of Capital


      Fri, 14 Feb 2014

      earlier-than-expected close to the ViroPharma acquisition. We continue to have a positive take on the ViroPharma acquisition, which strengthens the ..... incorporating more accretion from the ViroPharma acquisition into our 2014 forecast

    4. Shire's ViroPharma Acquisition Has Clear Synergies with Rare Disease Business


      Mon, 11 Nov 2013

      Shire has announced plans to acquire ViroPharma for $50 per share, or $4.2 billion ..... which amounts to a 64% premium to ViroPharma 's share price in September (prior ..... 25 per share fair value estimate for ViroPharma . However, after including $150 million

    5. Post-Vancocin, ViroPharma Remains Overvalued Due to Uncertainty Surrounding Pipeline Potential


      Thu, 1 Aug 2013

      ViroPharma 's second-quarter results continued to reflect the firm's ongoing ..... with strong Cinryze sales growth offsetting Vancocin’s decline. ViroPharma maintained its full-year guidance, which is in line with our expectations

    6. ViroPharma Focuses on Pipeline as Earnings Slide in 1Q


      Wed, 1 May 2013

      ViroPharma 's VPHM first-quarter results continued to reflect the firm's ongoing transformation ..... highly profitable antibiotic company into a rare-disease operation. ViroPharma lowered its full-year product sales guidance because of the steep

    7. Generic Competition for Vancocin Causes ViroPharma's Earnings to Hit Trough in 2012


      Wed, 27 Feb 2013

      During the fourth quarter, ViroPharma VPHM reported product sales that slightly ..... competition for Vancocin, and ViroPharma 's former breadwinning antibiotic ..... valuation remains heavily tied to ViroPharma 's ability to extend Cinryze's

    8. Full Impact of Generic Vancocin Evident in ViroPharma's Third Quarter


      Thu, 25 Oct 2012

      third quarter marked the first time that ViroPharma had to weather the impact of generic ..... sales drain has been swift: sales of ViroPharma 's former flagship antibiotic were ..... fourth year on the market. We think ViroPharma has done a great job of increasing disease

    9. BRIEF- ViroPharma jumps in premarket after FDA lifts hold on Cinryze testing


      Fri, 21 Sep 2012

      NEW YORK, Sept 21 (Reuters) - ViroPharma Inc : * Jumps 6.5 percent to $30 in premarket after FDA lifts hold on Cinryze testing

    10. Generic Entrants Take Toll on ViroPharma's 2Q, but Cinryze's Future Looks Brighter


      Thu, 9 Aug 2012

      ViroPharma VPHM reported second-quarter results that ..... for the firm's new core product. ViroPharma reported net sales of $94.6 million ..... significantly lower revenue levels, ViroPharma 's cost of goods sold still increased

    « Prev12345Next »
    Content Partners